Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.
You may also be interested in...
FTC Adds Public Citizen Alum To Senior Staff
David Vladeck, former head of Public Citizen Litigation Group, is named director of FTC’s Bureau of Consumer Protection as Chairman Leibowitz sets his leadership team.
FTC Adds Public Citizen Alum To Senior Staff
David Vladeck, former head of Public Citizen Litigation Group, is named director of FTC’s Bureau of Consumer Protection as Chairman Leibowitz sets his leadership team.
Biosimilar Interchangeability Does Not Create Substitution Under House Bills
While biosimilars legislation is seen as a means of lowering health care costs, interchangeability provisions in House bills creating a biosimilars approval pathway would not be enough to allow automatic substitution at the pharmacy level - the route to the highest savings